Plasma α-synuclein in patients with Parkinson's disease with and without treatment

Movement Disorders

Volumn 25, Issue 4, 2010, Pages 489-493

  Duran, Raquel ^a   Barrero, Francisco J ^b   Morales, Blas ^b   Luna, Juan D ^c   Ramirez, Manuel ^d   Vives, Francisco ^a  

^a UNIVERSITY OF GRANADA   (Spain)

^b HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^c UNIVERSITY OF GRANADA   (Spain)

^d UNIVERSITY OF JAÉN   (Spain)

Author keywords

Synuclein; Parkinson's disease; Parkinson's disease treatment; Pathogenesis; Plasma

Indexed keywords

ALPHA SYNUCLEIN; CARBIDOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; MONOAMINE OXIDASE INHIBITOR;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

AGED; ALPHA-SYNUCLEIN; ANTIPARKINSON AGENTS; DRUG THERAPY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE;

EID: 77949517145     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.22928     Document Type: Article

References (23)

1. Onyango IG. Mitochondrial dysfunction and oxidative stress in Parkinson's disease. Neurochem Res 2008;33:589-597.
2. Scherzer CR, Grass JA, Liao Z, et al. GATA transcription factors directly regulate the Parkinson's disease-linked gene α-synuclein. Proc Natl Acad Sci USA 2008;105:10907-10912.
3. Cookson MR. The biochemistry of Parkinson's disease. Annu Rev Biochem 2005;74:29-52.
4. Lee PH, Lee G, Park HJ, Bang OY, Joo IS, Huh K. The plasma alpha-synuclein levels in patients with Parkinson's disease and multiple system atrophy. J Neural Transm 2006;113:1435-1439.
5. Li QX, Mok SS, Laughton KM, et al. Plasma α-synuclein is decreased in subjects with Parkinson's disease. Exp Neurol 2007;204:583-588.
6. Borghi R, Marchese R, Negro A, et al. Full length α-synuclein is present in cerebrospinal fluid from Parkinson's disease and normal subjects. Neurosci Lett 2000;287:65-67.
7. El-Agnaf OMA, Salem SA, Paleologou KE, et al. α-Synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma. FASEB J 2003;17:1945-1947.
8. Barbour R, Kling K, Anderson JP, et al. Red blood cells are the major source of alpha-synuclein in blood. Neurodegener Dis 2008;5:55-59.
9. El-Agnaf OMA, Salem SA, Paleologou KE, et al. Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. FASEB J 2006;20:419-425.
10. Mollenhauer B, Trenkwalder C. Neurochemical biomarkers in the differential diagnosis of movement disorders. Mov Disord 2009;24:1411-1426.
11. Gelb D, Oliver E, Gilman S. Diagnostic criteria for Parkinson's disease. Arch Neurol 1999;56:33-39.
12. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-442.
13. Fjorback AW, Varming K, Jensen PH. Determination of α-synuclein concentration in human plasma using ELISA. Scand J Clin Lab Invest 2007;67:431-435.
14. Kim S, Seo JH, Suh YH. α-Synuclein, Parkinson's disease, and Alzheimer's disease. Parkinsonism Relat Disord 2004;10:S9-S13.
15. Probst A, Bloch A, Tolnay M. New insights into the pathology of Parkinson's disease: does the peripheral autonomic system become central? Eur J Neurol 2008;15 (Suppl 1):1-4.
16. Li QX, Campbell CV, McLean CA, et al. Platelet α- and γ-synuclein in Parkinson's disease and normal control subjects. J Alzheim Dis 2002;4:309-315.
17. Parihar MS, Parihar A, Fujita M, Hashimoto M, Ghafourifar P. Mitochondrial association of alpha-synuclein causes oxidative stress. Cell Mol Life Sci 2008;65:1272-1284.
18. Agil A, Duran R, Barrero F, et al. Plasma lípid peroxidation in sporadic Parkinson's disease. Role of the L-dopa. J Neurol Sci 2006;240:31-36.
19. Li W, Lesuisse C, Xu Y, Troncoso JC, Price DL, Lee MK. Stabilization of α-synuclein protein with aging and familial Parkinson's disease-linked A53T mutation. J Neurosci 2004;24:7400-7409.
20. Gasser T. Genomic and proteomic biomarkers for Parkinson disease. Neurology 2009;72:S27-S31.
21. Miller DW, Crawley A, Gwinn-Hardy K, et al. Unaltered alpha-synuclein blood levels in juvenile Parkinsonism with a Parkin Exon 4 deletion. Neurosci Lett 2005;374:189-191.
22. Miller DW, Hague SM, Clariman J, et al. Alpha-synuclein in blood and brain from familial Parkinsonism disease with SNCA locus triplication. Neurology 2004;62:1835-1838.
23. Sherer TB, Betarbet R, Stout AK, et al. An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage. J Neurosci 2002;22:7006-7015.